Axsome Therapeutics AXSM Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's operating lease right-of-use assets in other assets?
- Axsome Therapeutics (AXSM) reported operating lease right-of-use assets in other assets of $20.01M in Q1 2026.
- How has Axsome Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
- Axsome Therapeutics's operating lease right-of-use assets in other assets decreased by 14.1% year-over-year, from $23.29M to $20.01M.
- What is the long-term trend for Axsome Therapeutics's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Axsome Therapeutics's operating lease right-of-use assets in other assets has grown at a 64.4% compound annual growth rate (CAGR), from $1.74M to $20.86M.